Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H19N3O4 |
Molecular Weight | 389.4048 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CC(=O)N2[C@]([H])(Cc3c4ccccc4[nH]c3[C@@]2([H])c5ccc6c(c5)OCO6)C1=O
InChI
InChIKey=WOXKDUGGOYFFRN-IIBYNOLFSA-N
InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1
DescriptionSources: http://www.drugbank.ca/drugs/DB00820Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00820
Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf
Tadalafil is used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH). Part of the physiological process of erection involves the release of nitric oxide (NO) in the corpus cavernosum. This then activates the enzyme guanylate cyclase which results in increased levels of cyclic guanosine monophosphate (cGMP), leading to smooth muscle relaxation in the corpus cavernosum, resulting in increased inflow of blood and an erection. Tadalafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum. This means that, with tadalafil on board, normal sexual stimulation leads to increased levels of cGMP in the corpus cavernosum which leads to better erections. Without sexual stimulation and no activation of the NO/cGMP system, tadalafil should not cause an erection.Tadalafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by tadalafil enhances erectile function by increasing the amount of cGMP. Tadalafil is used for the treatment of erectile dysfunction.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22776546
Curator's Comment:: Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27581752 |
100.0 µM [IC50] | ||
Target ID: CHEMBL2097163 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24180640 |
5.1 µM [IC50] | ||
Target ID: CHEMBL2717 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21384413 |
0.05 µM [IC50] | ||
Target ID: CHEMBL1827 |
5.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CIALIS Approved UseCIALIS® is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of:
• erectile dysfunction (ED)
• the signs and symptoms of benign prostatic hyperplasia (BPH)
• ED and the signs and symptoms of BPH (ED/BPH) Launch Date1.06928642E12 |
|||
Primary | CIALIS Approved UseCIALIS® is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of:
• erectile dysfunction (ED)
• the signs and symptoms of benign prostatic hyperplasia (BPH)
• ED and the signs and symptoms of BPH (ED/BPH) Launch Date1.06928642E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
308.1 μg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29719379 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TADALAFIL blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7225 μg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29719379 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TADALAFIL blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29719379 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
TADALAFIL blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6% |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TADALAFIL unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
40 mg 1 times / day multiple, oral MTD Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
pregnant, 28 years (range: 20–39 years) n = 3 Health Status: pregnant Age Group: 28 years (range: 20–39 years) Sex: F Population Size: 3 Sources: |
Other AEs: Facial flushing, Anorexia... Other AEs: Facial flushing (grade 1, 2 patients) Sources: Anorexia (grade 1, 1 patient) |
20 mg 3 times / week multiple, oral Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: |
unhealthy, 54.9 years n = 4262 Health Status: unhealthy Condition: Erectile Dysfunction Age Group: 54.9 years Sex: M Population Size: 4262 Sources: |
Other AEs: Headache, Dyspepsia... Other AEs: Headache (7.7%) Sources: Dyspepsia (7%) Back pain (2.9%) Flushing (2.9%) Myalgia (3%) Abdominal pain upper (1.7%) |
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: erectile dysfunction Age Group: adult Sex: M Sources: |
|
500 mg single, oral Highest studied dose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anorexia | grade 1, 1 patient | 40 mg 1 times / day multiple, oral MTD Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
pregnant, 28 years (range: 20–39 years) n = 3 Health Status: pregnant Age Group: 28 years (range: 20–39 years) Sex: F Population Size: 3 Sources: |
Facial flushing | grade 1, 2 patients | 40 mg 1 times / day multiple, oral MTD Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
pregnant, 28 years (range: 20–39 years) n = 3 Health Status: pregnant Age Group: 28 years (range: 20–39 years) Sex: F Population Size: 3 Sources: |
Abdominal pain upper | 1.7% | 20 mg 3 times / week multiple, oral Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: |
unhealthy, 54.9 years n = 4262 Health Status: unhealthy Condition: Erectile Dysfunction Age Group: 54.9 years Sex: M Population Size: 4262 Sources: |
Back pain | 2.9% | 20 mg 3 times / week multiple, oral Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: |
unhealthy, 54.9 years n = 4262 Health Status: unhealthy Condition: Erectile Dysfunction Age Group: 54.9 years Sex: M Population Size: 4262 Sources: |
Flushing | 2.9% | 20 mg 3 times / week multiple, oral Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: |
unhealthy, 54.9 years n = 4262 Health Status: unhealthy Condition: Erectile Dysfunction Age Group: 54.9 years Sex: M Population Size: 4262 Sources: |
Myalgia | 3% | 20 mg 3 times / week multiple, oral Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: |
unhealthy, 54.9 years n = 4262 Health Status: unhealthy Condition: Erectile Dysfunction Age Group: 54.9 years Sex: M Population Size: 4262 Sources: |
Dyspepsia | 7% | 20 mg 3 times / week multiple, oral Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: |
unhealthy, 54.9 years n = 4262 Health Status: unhealthy Condition: Erectile Dysfunction Age Group: 54.9 years Sex: M Population Size: 4262 Sources: |
Headache | 7.7% | 20 mg 3 times / week multiple, oral Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: |
unhealthy, 54.9 years n = 4262 Health Status: unhealthy Condition: Erectile Dysfunction Age Group: 54.9 years Sex: M Population Size: 4262 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | no (co-administration study) Comment: taladafil had no clinically significant effect on PK of theophylline Page: 14.0 |
||
Page: 14.0 |
no | no (co-administration study) Comment: taladafil had no clinically significant effect on PK of theophylline Page: 14.0 |
||
Page: 14.0 |
no | no (co-administration study) Comment: Tadalafil had no clinically significant effect on exposure (AUC) to S-warfarin or R-warfarin, nor did tadalafil affect changes in prothrombin time induced by warfarin. Page: 14.0 |
||
Page: 14.0 |
no | no (co-administration study) Comment: Tadalafil had no clinically significant effect on exposure (AUC) to S-warfarin or R-warfarin, nor did tadalafil affect changes in prothrombin time induced by warfarin. Page: 14.0 |
||
Page: 14.0 |
no | no (co-administration study) Comment: taladafil had no clinically significant effect on exposure (AUC) to midazolam or lovastatin Page: 14.0 |
||
Page: 14.0 |
no | no (co-administration study) Comment: taladafil had no clinically significant effect on exposure (AUC) to midazolam or lovastatin Page: 14.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-368_Cialis_BioPharmr_P2.pdf#page=40 Page: 40.0 |
not significant [Ki 73 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-368_Cialis_BioPharmr_P2.pdf#page=49 Page: 49.0 |
major | yes (co-administration study) Comment: coadministration with ketoconazole (inhibitor) increased tadalafil exposure by 107%; ritonavir (inhibitor) increased tadalafil AUC by 124%; coadministration with rifampin (inducer) reduced taladafil AUC by 88%; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-368_Cialis_BioPharmr_P2.pdf#page=49 Page: 49.0 |
||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. | 2001 Feb |
|
Gateways to clinical trials. | 2002 Dec |
|
Effects of tadalafil on erectile dysfunction in men with diabetes. | 2002 Dec |
|
IC351 (tadalafil, Cialis): update on clinical experience. | 2002 Feb |
|
Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction. | 2002 Nov |
|
[Erectile dysfunction]. | 2002 Oct |
|
Gateways to clinical trials. | 2002 Oct |
|
Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature. | 2002 Oct 29 |
|
Family complains that "love drug'"will smear their name. | 2002 Sep 7 |
|
Tadalafil. | 2003 |
|
[How effective are PDE-5 inhibitors?]. | 2003 Apr |
|
The phosphodiesterase inhibitor 'war'. | 2003 Apr |
|
Effects of tadalafil on erectile dysfunction in men with diabetes. | 2003 Aug |
|
Coming attractions! New medications on the horizon for erectile dysfunction. | 2003 Aug |
|
Tadalafil in the treatment of erectile dysfunction. | 2003 Dec |
|
Tadalafil: a new agent for erectile dysfunction. | 2003 Feb |
|
New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction. | 2003 Jun |
|
[New treatment options for erectile dysfunction. Pharmacologic and nonpharmacologic options]. | 2003 Jun |
|
Pharmacological management of erectile dysfunction. | 2003 Mar |
|
Cardiovascular effects of tadalafil. | 2003 Nov 6 |
|
Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. | 2003 Nov 6 |
|
Overview of phosphodiesterase 5 inhibition in erectile dysfunction. | 2003 Nov 6 |
|
[Drug therapy of erectile dysfunction--the current status]. | 2003 Oct |
|
Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey. | 2003 Oct |
|
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues. | 2003 Oct 9 |
|
Novel PDE5 inhibitors for the treatment of male erectile dysfunction. | 2003 Oct-Nov |
|
Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. | 2004 Apr |
|
Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. | 2004 Apr |
|
Pills for erectile dysfunction: now there are three. | 2004 Apr |
|
A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. | 2004 Apr |
|
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy. | 2004 Feb |
|
Cialis is here. The soft sell. | 2004 Feb 2 |
|
Are they better than Viagra? Two new drugs for erectile dysfunction work like Viagra and carry similar risks and benefits. Their subtle differences, however, may make a difference for some men. | 2004 Jan |
|
[Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors]. | 2004 Jul |
|
The efficacy and safety of tadalafil: an update. | 2004 Jun |
|
Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra. | 2004 Mar 26 |
|
New drugs of 2003. | 2004 Mar-Apr |
|
Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone. | 2004 Oct |
Patents
Sample Use Guides
ED: Starting dose: 10 mg as needed prior to sexual activity. Increase to
20 mg or decrease to 5 mg based upon efficacy/tolerability. Improves
erectile function compared to placebo up to 36 hours post dose. Not to
be taken more than once per day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20555034
Increasing levels of tadalafil (1–25 uM) attenuated proliferation of human primary prostatic stromal cells (PrSCs) in a dose-dependent manner with concentrations above 5 uM showing highly significant effects
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C02KX52
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
||
|
FDA ORPHAN DRUG |
528316
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
CIALIS (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
||
|
NDF-RT |
N0000175599
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
ADCIRCA (AUTHORIZED: HYPERTENSION, PULMONARY)
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
||
|
NDF-RT |
N0000020026
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
||
|
FDA ORPHAN DRUG |
476415
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
TADALAFIL MYLAN (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
||
|
FDA ORPHAN DRUG |
228206
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
||
|
NCI_THESAURUS |
C2127
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
||
|
WHO-VATC |
QG04BE08
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
||
|
FDA ORPHAN DRUG |
509615
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
||
|
WHO-ATC |
G04BE08
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
||
|
LIVERTOX |
920
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
171596-29-5
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | |||
|
8136
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | |||
|
7299
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | |||
|
7303
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | |||
|
358263
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | RxNorm | ||
|
Tadalafil
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | |||
|
C429886
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | |||
|
742SXX0ICT
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | |||
|
1642879
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | USP-RS | ||
|
DB00820
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | |||
|
110635
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | |||
|
SUB12602MIG
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | |||
|
CHEMBL779
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | |||
|
C47743
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | |||
|
M10427
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | Merck Index | ||
|
171596-29-5
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | |||
|
2553
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY | |||
|
TADALAFIL
Created by
admin on Fri Jun 25 21:08:53 UTC 2021 , Edited by admin on Fri Jun 25 21:08:53 UTC 2021
|
PRIMARY |
ACTIVE MOIETY